Blueprint Medicines reported strong Q3 2024 results with a GAAP EPS beat of $0.08 and revenue beating by $0.71M, showing significant growth year-over-year.
OneMain (OMF) delivered earnings and revenue surprises of 6.78% and 1.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?